Laparoscopic, Robotic Surgeries Equivalent for Pancreatic Cancer

by U.S. Medicine

February 9, 2018

DALLAS—Pancreatic cancer patients increasingly are receiving minimally invasive pancreaticoduodenectomy (MIPD), but, according to a new study, there is not yet enough research on whether robotic (RPD) or laparoscopic (LPD) procedures lead to better outcomes.

That’s according to a retrospective study published recently in the journal Surgical Endoscopy.  A study team of researchers from the VA North Texas Healthcare System and the University of Texas Southwestern Medical Center used the National Cancer Database between 2010 and 2013 to compare perioperative, pathological and mid-term oncological outcomes between RPD and LPD.1

The researchers focused on 1,623 MIPD cases—90% of them LPD and 10% RPD. They found that most LPD (63%) and RPD (51%) cases were performed at institutions with a volume of five or fewer MIPDs per year.

Results indicated no differences in patient- and tumor-related factors between the groups. The majority of treated tumors were adenocarcinoma (90.1% for RPD and 89.1% for LPD), according to the study.

RPDs were more likely to be performed at academic centers (89.1%) compared to LPDs (68.1%, P < 0.001) and at higher-volume centers (median MIPD/year of 4.7 for RPD vs 3.6 for LPD, P < 0.001), study authors reported. No difference was documented, however, in the median number of examined lymph nodes, margin status, median length of stay, 90-day mortality or 30-day re-admission between groups. Median overall survival for pancreatic adenocarcinoma between LPD (20.7 months) and RPD (22.7 months; log-rank P = 0.445) also wasn’t significant. In addition, the one and three-year overall survival rates were 74 and 31% for LPD vs. 71 and 33% for RPD.

“In this national cohort of patients, LPD and RPD were associated with equivalent perioperative, pathological, and mid-term oncological outcomes,” the study authors concluded.

  1. Nassour I, Choti MA, Porembka MR, Yopp AC, Wang SC, Polanco PM. Robotic-assisted versus laparoscopic pancreaticoduodenectomy: oncological outcomes. Surg Endosc. 2017 Dec 26. doi: 10.1007/s00464-017-6002-2. [Epub ahead of print] PubMed PMID: 29280014.

Comments are closed here.

Related Articles

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

U.S. Medicine Recommends

More From research


VA Researcher Seeks to Include Veterans’ Voices in Healthcare Decisions

SEATTLE—It’s a big job to ensure that VA’s healthcare system is equipped to provide the best possible care to veterans. It might be an even bigger job to make sure that veterans across the country... View Article


First-Ever Study Focuses on How Well VHA Cares for TIA Patients

INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help avoid acute events altogether.


Link Between Pain, Brain Disruption in Gulf War Veterans

MADISON, WI — Chronic musculoskeletal pain (CMP) affects about one-fourth of the 700,000 veterans deployed during the Persian Gulf War in 1990-1991. A study in the journal Pain pointed out that the cause of their... View Article


VA Patients Lack Testing to Optimize CLL Treatment

SALT LAKE CITY — The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL), according to a report in the Journal of Clinical Oncology.1


Early Relapse After AHCT Bad Sign in Multiple Myeloma

ROCHESTER, MN — Duration of initial disease response remains a strong prognostic factor in multiple myeloma (MM), especially for upfront autologous hematopoietic cell transplant (AHCT) recipients. A study in the journal Leukemia hypothesized that new... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up